# Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

> **NCT06266091** · PHASE2 · COMPLETED · sponsor: **Wuhan YZY Biopharma Co., Ltd.** · enrollment: 115 (actual)

## Conditions studied

- Malignant Ascites

## Interventions

- **DRUG:** M701
- **DRUG:** paracentesis

## Key facts

- **NCT ID:** NCT06266091
- **Lead sponsor:** Wuhan YZY Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-24
- **Primary completion:** 2024-02-14
- **Final completion:** 2024-08-01
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06266091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06266091, "Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06266091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*